130 related articles for article (PubMed ID: 32130732)
1. Diagnostic deep-targeted next-generation sequencing assessment of TP53 gene mutations in multiple myeloma from the whole bone marrow.
Petrackova A; Minarik J; Sedlarikova L; Libigerova T; Hamplova A; Krhovska P; Balcarkova J; Pika T; Papajik T; Kriegova E
Br J Haematol; 2020 May; 189(4):e122-e125. PubMed ID: 32130732
[No Abstract] [Full Text] [Related]
2. Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature.
Lionetti M; Barbieri M; Manzoni M; Fabris S; Bandini C; Todoerti K; Nozza F; Rossi D; Musto P; Baldini L; Neri A
Oncotarget; 2016 Apr; 7(16):21353-61. PubMed ID: 26870891
[TBL] [Abstract][Full Text] [Related]
3. Ultradeep, targeted sequencing reveals distinct mutations in blood compared to matched bone marrow among patients with multiple myeloma.
Coffey DG; Wu QV; Towlerton AMH; Ornelas S; Morales AJ; Xu Y; Green DJ; Warren EH
Blood Cancer J; 2019 Sep; 9(10):77. PubMed ID: 31570697
[No Abstract] [Full Text] [Related]
4. p53 gene mutations are rare in patients but common in patient-originating cell lines in multiple myeloma.
Ollikainen H; Syrjänen S; Koskela K; Pelliniemi TT; Pulkki K
Scand J Clin Lab Invest; 1997 Jul; 57(4):281-9. PubMed ID: 9249875
[TBL] [Abstract][Full Text] [Related]
5. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.
Rasche L; Chavan SS; Stephens OW; Patel PH; Tytarenko R; Ashby C; Bauer M; Stein C; Deshpande S; Wardell C; Buzder T; Molnar G; Zangari M; van Rhee F; Thanendrarajan S; Schinke C; Epstein J; Davies FE; Walker BA; Meissner T; Barlogie B; Morgan GJ; Weinhold N
Nat Commun; 2017 Aug; 8(1):268. PubMed ID: 28814763
[TBL] [Abstract][Full Text] [Related]
6. N-ras and p53 gene mutations are very rare events in multiple myeloma.
Yasuga Y; Hirosawa S; Yamamoto K; Tomiyama J; Nagata K; Aokia N
Int J Hematol; 1995 Aug; 62(2):91-7. PubMed ID: 8590778
[TBL] [Abstract][Full Text] [Related]
7. Bone marrow morphologic features, MyPRS, and gene mutation correlations in plasma cell myeloma.
Hao Y; Khaykin D; Machado L; van den Akker T; Houldsworth J; Barlogie B; Hussein S; El Jamal SM; Petersen B; Teruya-Feldstein J
Mod Pathol; 2020 Feb; 33(2):188-195. PubMed ID: 31375765
[TBL] [Abstract][Full Text] [Related]
8. The frequency and clinical outcome of mono-hit and multi-hit TP53 aberrations in newly diagnosed multiple myeloma.
Sreedharanunni S; Singla S; Balakrishnan A; Singh A; Jamwal M; Singh N; Singh C; Jandial A; Lad D; Sharma P; Sachdeva MUS; Malhotra P; Das R
Pathology; 2024 Jun; 56(4):556-564. PubMed ID: 38413253
[TBL] [Abstract][Full Text] [Related]
9. A Rare Episode of Extensive Bone Marrow Necrosis in a Chemotherapy-naïve Patient with Multiple Myeloma Exhibiting
Jeon K; Kim HJ; Kim M; Lee YK
Ann Clin Lab Sci; 2020 Jan; 50(1):136-139. PubMed ID: 32161023
[TBL] [Abstract][Full Text] [Related]
10. Rare occurrence of P53 gene mutations in multiple myeloma.
Preudhomme C; Facon T; Zandecki M; Vanrumbeke M; Laï JL; Nataf E; Loucheux-Lefebvre MH; Kerckaert JP; Fenaux P
Br J Haematol; 1992 Jul; 81(3):440-3. PubMed ID: 1390218
[TBL] [Abstract][Full Text] [Related]
11. Multiple myeloma: monoallelic deletions of the tumor suppressor genes TP53 and RB1 in long-term follow-up.
Carlebach M; Amiel A; Gaber E; Radnay J; Manor Y; Fejgin M; Lishner M
Cancer Genet Cytogenet; 2000 Feb; 117(1):57-60. PubMed ID: 10700868
[TBL] [Abstract][Full Text] [Related]
12. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
13. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
14. Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients.
Vij R; Mazumder A; Klinger M; O'Dea D; Paasch J; Martin T; Weng L; Park J; Fiala M; Faham M; Wolf J
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):131-139.e1. PubMed ID: 24629890
[TBL] [Abstract][Full Text] [Related]
15. Detection of TP53/PIK3CA Mutations in Cell-Free Plasma DNA From Metastatic Breast Cancer Patients Using Next Generation Sequencing.
Nakauchi C; Kagara N; Shimazu K; Shimomura A; Naoi Y; Shimoda M; Kim SJ; Noguchi S
Clin Breast Cancer; 2016 Oct; 16(5):418-423. PubMed ID: 27265061
[TBL] [Abstract][Full Text] [Related]
16. Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations.
Peterson JF; Rowsey RA; Marcou CA; Pearce KE; Williamson CM; Frederick LA; Greipp PT; Ketterling RP; Kumar S; Viswanatha DS; Polley MY; Fink JM; Reichard KK; Van Dyke DL; Baughn LB
Blood Cancer J; 2019 Feb; 9(3):20. PubMed ID: 30783078
[No Abstract] [Full Text] [Related]
17. A Next-Generation Sequencing Strategy for Evaluating the Most Common Genetic Abnormalities in Multiple Myeloma.
Jiménez C; Jara-Acevedo M; Corchete LA; Castillo D; Ordóñez GR; Sarasquete ME; Puig N; Martínez-López J; Prieto-Conde MI; García-Álvarez M; Chillón MC; Balanzategui A; Alcoceba M; Oriol A; Rosiñol L; Palomera L; Teruel AI; Lahuerta JJ; Bladé J; Mateos MV; Orfão A; San Miguel JF; González M; Gutiérrez NC; García-Sanz R
J Mol Diagn; 2017 Jan; 19(1):99-106. PubMed ID: 27863261
[TBL] [Abstract][Full Text] [Related]
18. Monitoring minimal residual disease in the bone marrow using next generation sequencing.
Rustad EH; Boyle EM
Best Pract Res Clin Haematol; 2020 Mar; 33(1):101149. PubMed ID: 32139014
[TBL] [Abstract][Full Text] [Related]
19. Next-Generation Sequencing Revealed TP53 Mutations to Be Malignant Marker for Intraductal Papillary Mucinous Neoplasms That Could Be Detected Using Pancreatic Juice.
Takano S; Fukasawa M; Kadokura M; Shindo H; Takahashi E; Hirose S; Maekawa S; Mochizuki K; Kawaida H; Itakura J; Katoh R; Fujii H; Sato T; Enomoto N
Pancreas; 2017; 46(10):1281-1287. PubMed ID: 28930868
[TBL] [Abstract][Full Text] [Related]
20. Relevance of TP53 for CLL diagnostics.
Catherwood MA; Gonzalez D; Donaldson D; Clifford R; Mills K; Thornton P
J Clin Pathol; 2019 May; 72(5):343-346. PubMed ID: 30712002
[No Abstract] [Full Text] [Related]
[Next] [New Search]
